Word

RENBIO

Status

Pending

Status Code

733

Status Date

Friday, December 8, 2023

Serial Number

90309237

Mark Type

4000

Filing Date

Tuesday, November 10, 2020

Published for Opposition

Tuesday, November 9, 2021

Trademark Owner History

RENBIO, INC. - 1st New Owner After Publication
RenBio, Inc. - Owner At Publication

Classifications

5 Chemical preparations for gene delivery pharmaceuticals for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for gene therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for gene therapy analysis; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions; Pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Biological preparations for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Nucleic acid sequences for medical purposes; Pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals

1 Biological products, namely, DNA circle, DNA primers, linear DNA and buffers for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals; Biological products, namely, antibodies, multi-specific antibodies, antibody fragments, proteins, chimeric proteins, drug conjugates and enzymes, for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals

10 Medical apparatus for the administration of biopharmaceuticals and vaccines, namely, drug delivery devices and systems being pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs; medical devices, namely, pulse and waveform generators for electroporation mediated administration of drugs to humans and animals; delivery systems comprised of pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs for administration of biopharmaceuticals and vaccines for the preventive or treatment of disease in humans and animals; handheld medical systems and devices comprised of pulse and waveform generators using electroporation for the prevention or treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders in humans and animals; handheld clinical delivery systems and devices comprised of pulse and waveform generators for the application of electrical fields in tissue, in particular muscle and skin, in conjunction with the administration of biopharmaceuticals

42 Medical and scientific research in the field of drug delivery devices; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines

Trademark Events

Dec 12, 2023

Notice Of Approval Of Extension Request E-Mailed

Dec 8, 2023

Sou Extension 4 Granted

Dec 8, 2023

Sou Extension 4 Filed

Dec 8, 2023

Sou Teas Extension Received

Jun 22, 2023

Notice Of Approval Of Extension Request E-Mailed

Jun 20, 2023

Sou Extension 3 Granted

Jun 20, 2023

Sou Extension 3 Filed

Jun 20, 2023

Sou Teas Extension Received

Jan 5, 2023

Notice Of Approval Of Extension Request E-Mailed

Jan 3, 2023

Sou Extension 2 Granted

Jan 3, 2023

Sou Extension 2 Filed

Jan 3, 2023

Sou Teas Extension Received

Jul 5, 2022

Notice Of Approval Of Extension Request E-Mailed

Jul 1, 2022

Sou Extension 1 Granted

Jul 1, 2022

Sou Extension 1 Filed

Jul 1, 2022

Sou Teas Extension Received

May 19, 2022

Automatic Update Of Assignment Of Ownership

Jan 4, 2022

Noa E-Mailed - Sou Required From Applicant

Nov 9, 2021

Official Gazette Publication Confirmation E-Mailed

Nov 9, 2021

Published For Opposition

Oct 20, 2021

Notification Of Notice Of Publication E-Mailed

Oct 7, 2021

Approved For Pub - Principal Register

Oct 6, 2021

Teas/Email Correspondence Entered

Oct 5, 2021

Correspondence Received In Law Office

Oct 5, 2021

Teas Response To Office Action Received

Sep 9, 2021

Applicant/Correspondence Changes (Non-Responsive) Entered

Sep 9, 2021

Teas Change Of Correspondence Received

Sep 9, 2021

Teas Change Of Owner Address Received

Apr 5, 2021

Notification Of Non-Final Action E-Mailed

Apr 5, 2021

Non-Final Action E-Mailed

Apr 5, 2021

Non-Final Action Written

Apr 2, 2021

Assigned To Examiner

Jan 8, 2021

New Application Office Supplied Data Entered

Nov 13, 2020

New Application Entered